• Teva bid to buy BioXcel’s dexmedetomidine sublingual film asset in a court-supervised Chapter 11 sale, not the whole company.
• Offer terms: USD 57.5 million upfront payment for worldwide rights, with up to USD 67.5 million in contingent payments.
• Asset includes IGALMI, marketed for supervised use, with BXCL501 under FDA review for potential at-home treatment of agitation in adults.
• FDA target action date set for Nov. 14, 2026; contingent payments tied to approval timing and sales milestones.
• Deal outcome hinges on auction results, bankruptcy court sign-off, higher bids, and customary closing conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teva Pharmaceutical Industries Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608280617OMX_____CNEWS_EN_GNW1001259869_en) on August 28, 2026, and is solely responsible for the information contained therein.